On December 22, 2021 Targovax ASA’s (the "Company") stock exchange reported that published on 15 December 2021, regarding the final result of the rights issue of 101,744,186 new shares in the Company (the "Offer Shares") at a subscription price of NOK 1.72 per Offer Share (the "Rights Issue") (Press release, Targovax, DEC 22, 2021, View Source [SID1234597595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The share capital increase pertaining to the Rights Issue has now been registered in the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company’s new share capital is NOK 18,832,659.10 divided into 188,326,591 shares, each with a nominal value of NOK 0,10.

Delivery of the Offer Shares in the Norwegian Central Securities Depository (the VPS) to the subscribers having been allocated Offer Shares in the Rights Issue is expected to take place tomorrow, on 23 December 2021, however trading in the Offer Shares on the Oslo Stock Exchange with ordinary T+2 settlement may accordingly commence now.